BRD4 and head and neck squamous cell carcinoma: Also, successful results in delaying acquired cetuximab resistance were shown when JQ1 or BRD4 knockdown were used in combination with cetuximab in HNSCC cell models or patient-derived xenografts.19 In our short time course therapeutic model, we could not determine the time of resistance of development, but we observed the inhibitory effects of JQ1 alone or in combination with EGFR blockade.